ORBIMED ADVISORS LLC - 08 Jun 2026 Form 4 Insider Report for Shattuck Labs, Inc. (STTK)

Reporting relationship
Director
Issuer ticker
STTK
Reported as of
08 Jun 2026
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
09 Jun 2026, 20:58:33 UTC
Prior SEC filing
01 Jun 2026
Next SEC filing
15 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Carl L. Gordon, Member of OrbiMed Advisors LLC

Key filing fact

ORBIMED ADVISORS LLC filed Form 4 for Shattuck Labs, Inc. (STTK) on 09 Jun 2026.

Key facts

  • This page summarizes ORBIMED ADVISORS LLC's Form 4 filing for Shattuck Labs, Inc. (STTK).
  • 4 reported transactions and 12 derivative rows are listed below.
  • Accepted by SEC: 09 Jun 2026, 20:58.

Change

  • Previous filing in this sequence was filed on 01 Jun 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (3)

CIK 0001055951 Primary reporting owner

ORBIMED ADVISORS LLC

Relationship
Director
Address
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
Signature
/s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Signature date
09 Jun 2026
CIK 0001920574

OrbiMed Capital GP IX LLC

Relationship
Director
Address
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
Signature
/s/ Carl L. Gordon, Member of OrbiMed Capital GP IX LLC
Signature date
09 Jun 2026
CIK 0001808744

OrbiMed Genesis GP LLC

Relationship
Director
Address
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK
Signature
/s/ Carl L. Gordon, Member of OrbiMed Genesis GP LLC
Signature date
09 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

STTK holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
5,255,106
Date
08 Jun 2026
Ownership
See Footnote
Footnotes
F3, F5
STTK holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
5,255,106
Date
08 Jun 2026
Ownership
See Footnote
Footnotes
F3, F5
STTK holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
5,255,106
Date
08 Jun 2026
Ownership
See Footnote
Footnotes
F3, F5
STTK holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1,051,021
Date
08 Jun 2026
Ownership
See Footnote
Footnotes
F4, F5
STTK holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1,051,021
Date
08 Jun 2026
Ownership
See Footnote
Footnotes
F4, F5
STTK holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
1,051,021
Date
08 Jun 2026
Ownership
See Footnote
Footnotes
F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

STTK transaction Derivative

Pre-Funded Warrants (right to buy)

Conversion of derivative security

Transaction value
Shares
+15,366,490
Change %
+152%
Price
Shares after
25,477,874
Date
08 Jun 2026
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
15,366,490
Exercise price
$0.000100
Footnotes
F1, F2, F3, F5
STTK transaction Derivative

Pre-Funded Warrants (right to buy)

Conversion of derivative security

Transaction value
Shares
+15,366,490
Change %
+152%
Price
Shares after
25,477,874
Date
08 Jun 2026
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
15,366,490
Exercise price
$0.000100
Footnotes
F1, F2, F3, F5
STTK transaction Derivative

Pre-Funded Warrants (right to buy)

Conversion of derivative security

Transaction value
Shares
+15,366,490
Change %
+152%
Price
Shares after
25,477,874
Date
08 Jun 2026
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
15,366,490
Exercise price
$0.000100
Footnotes
F1, F2, F3, F5
STTK transaction Derivative

Pre-Funded Warrants (right to buy)

Conversion of derivative security

Transaction value
Shares
+3,073,298
Change %
+152%
Price
Shares after
5,095,575
Date
08 Jun 2026
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
3,073,298
Exercise price
$0.000100
Footnotes
F1, F2, F4, F5
STTK transaction Derivative

Pre-Funded Warrants (right to buy)

Conversion of derivative security

Transaction value
Shares
+3,073,298
Change %
+152%
Price
Shares after
5,095,575
Date
08 Jun 2026
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
3,073,298
Exercise price
$0.000100
Footnotes
F1, F2, F4, F5
STTK transaction Derivative

Pre-Funded Warrants (right to buy)

Conversion of derivative security

Transaction value
Shares
+3,073,298
Change %
+152%
Price
Shares after
5,095,575
Date
08 Jun 2026
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
3,073,298
Exercise price
$0.000100
Footnotes
F1, F2, F4, F5
STTK transaction Derivative

Common Warrants (right to buy)

Conversion of derivative security

Transaction value
Shares
-15,366,490
Change %
-100%
Price
Shares after
0
Date
08 Jun 2026
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
15,366,490
Exercise price
$1.08
Footnotes
F1, F2, F3, F5
STTK transaction Derivative

Common Warrants (right to buy)

Conversion of derivative security

Transaction value
Shares
-15,366,490
Change %
-100%
Price
Shares after
0
Date
08 Jun 2026
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
15,366,490
Exercise price
$1.08
Footnotes
F1, F2, F3, F5
STTK transaction Derivative

Common Warrants (right to buy)

Conversion of derivative security

Transaction value
Shares
-15,366,490
Change %
-100%
Price
Shares after
0
Date
08 Jun 2026
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
15,366,490
Exercise price
$1.08
Footnotes
F1, F2, F3, F5
STTK transaction Derivative

Common Warrants (right to buy)

Conversion of derivative security

Transaction value
Shares
-3,073,298
Change %
-100%
Price
Shares after
0
Date
08 Jun 2026
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
3,073,298
Exercise price
$1.08
Footnotes
F1, F2, F4, F5
STTK transaction Derivative

Common Warrants (right to buy)

Conversion of derivative security

Transaction value
Shares
-3,073,298
Change %
-100%
Price
Shares after
0
Date
08 Jun 2026
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
3,073,298
Exercise price
$1.08
Footnotes
F1, F2, F4, F5
STTK transaction Derivative

Common Warrants (right to buy)

Conversion of derivative security

Transaction value
Shares
-3,073,298
Change %
-100%
Price
Shares after
0
Date
08 Jun 2026
Ownership
See Footnote
Underlying class
Common Stock
Underlying amount
3,073,298
Exercise price
$1.08
Footnotes
F1, F2, F4, F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

On August 4, 2025, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Persons. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold to the Reporting Persons in a private placement which closed on August 25, 2025 (the "Closing Date") an aggregate of 6,306,127 shares of the Issuer's common stock ("Shares") and pre-funded warrants ("Pre-Funded Warrants") to purchase up to an aggregate of 12,133,661 Shares. The Reporting Persons also received accompanying common warrants ("Common Warrants") to purchase up to an aggregate of 18,439,799 Shares or, if so elected by Reporting Persons, Pre-Funded Warrants. The price per Share and accompanying Common Warrant was $0.8677. The price per Pre-Funded Warrant and accompanying Common Warrant was $0.8676. On June 8, 2026, the Reporting Persons exercised their Common Warrants in exchange for an equal amount of Pre-Funded Warrants.

Footnote F2

The Pre-Funded Warrants are exercisable at any time after the date of issuance and the Common Warrants were exercisable at any time after the Closing Date, in each case subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants will expire once exercised in full. The Common Warrants would have expired on the 30th day after the date on which the data from the single ascending dose and multiple ascending dose portions of the Issuer's Phase 1 clinical trial of SL-325, including receptor occupancy and safety data, and the design of the planned Phase 2 clinical trial(s) have been announced publicly.

Footnote F3

These securities are held of record by OrbiMed Private Investments IX, LP ("OPI IX"). OrbiMed Capital GP IX LLC ("GP IX") is the general partner of OPI IX. OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisers Act of 1940, as amended, is the managing member of GP IX. By virtue of such relationships, GP IX and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI XI. OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI IX.

Footnote F4

These securities are held of record by OrbiMed Genesis Master Fund, L.P. ("Genesis Master Fund"). OrbiMed Genesis GP LLC ("Genesis GP") is the general partner of Genesis Master Fund. OrbiMed Advisors is the managing member of Genesis GP. By virtue of such relationships, Genesis GP and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by Genesis Master Fund. OrbiMed Advisors exercises voting and investment power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by Genesis Master Fund.

Footnote F5

This report on Form 4 is jointly filed by OrbiMed Advisors, GP IX, and Genesis GP. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors has designated a representative, Mona Ashiya ("Ashiya"), a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons or Ashiya is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .